Lixte Biotechnology Holdings, I LIXT

Competitive advantage analysis · healthcare

Corporate Default
Overall moat score
34/100
Developing

Ranked against 712 peers in Biotechnology

About Lixte Biotechnology Holdings, I

Lixte Biotechnology Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on identifying targets for cancer drug development, and developing and commercializing cancer therapies. Its lead product candidate, LB-100 is in phase 1b clinical trials combined with Atezolizumab for patients with microsatellite stable metastatic colorectal cancer. The company's LB-100 combined with doxorubicin in advanced soft tissue sarcoma is under Phase 1b portion; … Full LIXT analysis →

Key risks

  • Elevated Debt Risk Debt serviceability is weak (score 0.16), raising refinancing risk.
  • Weak or Negative Cash Flow Cash generation is weak (score 0.00), limiting financial flexibility.

The dashed ring is the peer median. Defense scores are percentile ranks against peers, so 50 is roughly the typical company in this group.

Upgrade to unlock the signals and evidence behind each defense.

Premium access

Unlock full defense analysis

Get key signals, strengths, and risks for every moat dimension.

Upgrade to Premium Unlock all moat defenses and evidence.

Pricing Power

Insufficient Data
—
Premium

Signals, strengths and risks for Pricing Power

Premium

Signals, strengths and risks for Cost Advantage

Premium

Signals, strengths and risks for Customer Stickiness

Premium

Signals, strengths and risks for Capital Efficiency

Premium

Signals, strengths and risks for Resilience

Premium

Signals, strengths and risks for Scale & Market Position

Where LIXT ranks in Biotechnology

Lixte Biotechnology Holdings, I ranks #461 of 713 scored companies in Biotechnology by moat score — the top 65%. The widest moat in the group is Royalty Pharma plc (RPRX) at 85/100.

# Company Moat score Rating
457 RAPT Therapeutics, Inc. RAPT 34/100 Developing
458 Exicure, Inc. XCUR 34/100 Developing
459 MetaVia Inc. MTVA 34/100 Developing
460 Polyrizon Ltd. PLRZ 34/100 Developing
461 Lixte Biotechnology Holdings, I LIXT 34/100 Developing
462 Atossa Therapeutics, Inc. ATOS 34/100 Developing
463 Lexaria Bioscience Corp. LEXX 34/100 Developing
464 Molecular Partners AG MOLN 33/100 Developing
465 Psyence Biomedical Ltd. PBM 33/100 Developing

See every Biotech / Pre-Revenue company ranked by moat score →

How LIXT scores on the Corporate Default defenses

Pricing Power

Not measurable · 20% of the moat score

Pricing power is the ability to raise prices without losing volume.

Cost Advantage

Not measurable · 15% of the moat score

A cost advantage means delivering the same product for structurally less — better purchasing, denser distribution, a more automated process.

Customer Stickiness

Not measurable · 15% of the moat score

Stickiness is what makes revenue repeat without being re-won every year.

Capital Efficiency

Score 38 · 18% of the moat score

Capital efficiency asks what the company earns on the money tied up in the business.

Resilience

Score 27 · 17% of the moat score

Resilience is the capacity to get through a bad year on its own terms — enough liquidity, enough interest cover, and enough cash generation to avoid a rescue financing or a forced sale.

Scale & Market Position

Not measurable · 15% of the moat score

Scale matters only when it converts into economics.

How each Corporate Default defense is measured, in full →

Understanding LIXT's moat

What is Lixte Biotechnology Holdings, I's moat score?

Lixte Biotechnology Holdings, I (LIXT) scores 34 out of 100 on the StatsAlpha Moat Map, which rates its competitive advantage as developing. It ranks #461 of 713 scored companies in Biotechnology, the top 65%. The score is a weighted composite of 6 competitive defenses, each measured against industry peers of 712 companies in Biotechnology. Its strongest defense is Capital Efficiency (38/100) and its weakest is Resilience (27/100).

How does Lixte Biotechnology Holdings, I compare with other Biotechnology companies?

Lixte Biotechnology Holdings, I ranks #461 of 713 scored companies in Biotechnology by moat score. The widest moat in Biotechnology is Royalty Pharma plc (RPRX) at 85/100. The companies ranked closest are Polyrizon Ltd. (PLRZ) at 34 just above it and Atossa Therapeutics, Inc. (ATOS) at 34 just below it.

How is the moat score calculated?

Each company is scored with an industry-specific template — Corporate Default in this case, chosen because the defenses that matter to a bank are not the ones that matter to a software company. Every defense combines several financial signals, and each signal is measured as a percentile against a peer group of 712 companies in Biotechnology. The defenses are then weighted to produce the overall score out of 100.

Why is Lixte Biotechnology Holdings, I scored with the Corporate Default template?

Most public companies sell a product or a service at a margin, so the moat question is whether that margin survives contact with competitors. The Corporate template scores the six defenses that show up in a general operating company's financial signature: whether it can hold price, produce more cheaply than rivals, keep its customers, earn a return above its cost of capital, withstand a downturn, and turn size into economics.

Which competitive defenses are measured for Lixte Biotechnology Holdings, I?

The Corporate Default template measures 6 defenses, and LIXT scores: Pricing Power (not measurable), Cost Advantage (not measurable), Customer Stickiness (not measurable), Capital Efficiency (38), Resilience (27), Scale & Market Position (not measurable). Each is scored independently as a percentile against peers, so a company can be strong on one and weak on another — the overall score reflects how those defenses are weighted for this industry.

Send Feedback
Please select a category.
0/1000